Transdermal (TDS) Oxybutynin (Oxytrol(r)) in Overactive Bladder

• Status: Completed
• Trial end date: 2005-05-01
• Target enrollment: 0
• Participant gender: All

Summary

This study evaluates changes in health related quality of life outcomes in patients using Oxytrol(r)

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Watson Pharmaceuticals
• Treatments: Mandelic Acids; Oxybutynin

Criteria

Inclusion Criteria:

• Adult patients with one or more symptom of overactive bladder, including urge urinary incontinence, urgency and/or frequency

Exclusion Criteria:

• Patients for whom Oxytrol(r) is contraindicated.

• Patients treated with Oxytrol(r) prior to participation in this study.

• Patients residing in long-term care facilities or nursing homes.